First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $18.9B — +4.5% growth in a single year.
What Moves the Stock
1Respironics recall resolution progress: litigation settlements, FDA consent decree compliance, return to market timing for sleep apnea devices
2Order intake growth in Diagnosis & Treatment: hospital capital equipment spending trends, particularly in China (15% of revenue) and North America (35% of revenue)
3Sleep & Respiratory Care revenue recovery: market share recapture from competitors (ResMed, Fisher & Paykel), new product launches post-recall
4Free cash flow generation and debt reduction: ability to deleverage from €8B+ net debt position while funding recall costs
5Margin expansion trajectory: progress toward 11-12% adjusted EBITA margin targets through cost restructuring and portfolio mix shift
6Diagnosis & Treatment (~55% of revenue): CT scanners, MRI systems, X-ray equipment, ultrasound devices, interventional X-ray systems sold to hospitals and imaging centers
7Connected Care (~30% of revenue): Patient monitoring systems, hospital informatics, sleep & respiratory care devices (currently depressed due to recall), emergency care solutions
8Personal Health (~15% of revenue): Electric toothbrushes (Sonicare brand), mother & child care products, male grooming devices sold through retail and e-commerce
value/turnaround - The stock attracts value investors betting on recall resolution and margin recovery…
Rising interest rates negatively impact Philips through three channels: (1) higher financing costs on €8B+ net debt position…
Watch on earnings: Hospital capital equipment spending trends in North America and Europe (35% and 40% of revenue respectively), China healthcare infrastructure investment and medical device import policies (15% of revenue exposure), EUR/USD exchange rate (60% of revenue outside Eurozone, significant translation impact).
One Sentence Summary:
Koninklijke Philips: the story is balanced — respironics recall resolution progress: litigation settlements, fda consent decree compliance.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.